American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Patient-reported outcomes from the Beamion LUNG-1 trial showed sustained improvements in physical functioning and symptom burden, with low side effect severity, supporting zongertinib’s potential in advanced NSCLC. Read More ›

Videos

Safety and Efficacy of Sevabertinib (BAY 2927088) in HER2-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): Results From the Phase I/II SOHO-01 Trial

By Beth Sandy, MSN, CRNP, FAPO

ASCO 2025 - Non-Small Cell Lung Cancer

The SOHO-01 trial highlights the manageable safety and promising efficacy of sevabertinib (BAY 2927088) in patients with pretreated or untreated HER2-mutant NSCLC. Read More ›

Videos

Safety of Imlunestrant in ER-Positive, HER2-Negative Advanced Breast Cancer: EMBER-3 Trial Results

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

EMBER-3 trial findings position imlunestrant monotherapy or in combination with abemaciclib as a promising, safe and effective oral therapeutic option for treating estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Videos

Promising Results for Elacestrant Combinations in ER-Positive, HER2-Negative Metastatic Breast Cancer: ELEVATE Trial Findings

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

Elacestrant in combination with ribociclib or everolimus demonstrates promising efficacy and manageable safety in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who experienced disease progression after endocrine therapy plus CDK4/6 inhibitors, Read More ›

Videos

SERENA-6 Phase 3 Trial: Camizestrant Plus CDK4/6 Inhibitor for ctDNA-Guided Treatment of ESR1 Mutations in HR-Positive, HER2-Negative Advanced Breast Cancer

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

The SERENA-6 trial reveals camizestrant's potential to improve outcomes in hormone receptor (HR)-positive, HER2-negative breast cancer by utilizing circulating tumor DNA (ctDNA)-guided therapy towards ESR1 mutations before disease progression. Read More ›

Videos

Patient-Reported Outcomes of Imlunestrant in EMBER-3 Trial for ER-Positive, HER2-Negative Advanced Breast Cancer

By Hope S. Rugo, MD, FASCO

ASCO 2025 - Breast Cancer Faculty Commentary

Patient-reported outcomes from EMBER-3 demonstrate that imlunestrant improves global health status/quality of life and physical function in patients with ESR1 mutations in estrogen receptor (ER)-positive, HER2-negative advanced breast cancer. Read More ›

Wrap-Up

Phase 2 Study of BEBT-209 Plus Gemcitabine and Carboplatin in Metastatic TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of BEBT-209 with gemcitabine and carboplatin showed promising efficacy and a tolerable safety profile in metastatic triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

NeoSTAR Arm A2: Evaluating Sacituzumab Govitecan and Pembrolizumab as Neoadjuvant Therapy for Early-Stage TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

Sacituzumab govitecan and pembrolizumab combination therapy showed promising clinical benefit in early-stage triple-negative breast cancer (TNBC). Read More ›

Wrap-Up

Efficacy and Safety of Camrelizumab, Apatinib, and Chemotherapy as Neoadjuvant Therapy for Stage II-III TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of camrelizumab, apatinib, and chemotherapy shows favorable outcomes in the neoadjuvant setting for stage II-III triple-negative breast cancer (TNBC), particularly in patients with programmed death-ligand 1 positivity. Read More ›

Wrap-Up

Phase 3 Trial of Benmelstobart Plus Anlotinib Versus Nab-Paclitaxel in First-Line Treatment of Recurrent or Metastatic TNBC

ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer

The combination of benmelstobart and anlotinib showed a numerical, though not a statistically significant improvement in progression-free survival and overall survival over nab-paclitaxel in recurrent or metastatic triple-negative breast cancer (TNBC). Read More ›

American Society of Clinical Oncology (ASCO)

Page 1 of 31